Neurotherapeutics

, Volume 14, Issue 2, pp 265–273

Medulloblastoma: Molecular Classification-Based Personal Therapeutics

  • Tenley C. Archer
  • Elizabeth L. Mahoney
  • Scott L. Pomeroy
Review

DOI: 10.1007/s13311-017-0526-y

Cite this article as:
Archer, T.C., Mahoney, E.L. & Pomeroy, S.L. Neurotherapeutics (2017) 14: 265. doi:10.1007/s13311-017-0526-y

Abstract

Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies.

Keywords

Medulloblastoma WHO MYC SHH WNT Genomic DNA methylation Subgroups Group 3 Group 4 

Supplementary material

13311_2017_526_MOESM1_ESM.pdf (1.2 mb)
ESM 1(PDF 1224 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2017

Authors and Affiliations

  • Tenley C. Archer
    • 1
    • 2
  • Elizabeth L. Mahoney
    • 1
  • Scott L. Pomeroy
    • 1
    • 2
  1. 1.Department of NeurologyBoston Children’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations